Ramesh Nachimuthu
Overview
Explore the profile of Ramesh Nachimuthu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
506
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manohar P, Loh B, Elangovan N, Loganathan A, Nachimuthu R, Leptihn S
Microbiol Spectr
. 2024 Nov;
:e0260624.
PMID: 39526758
No abstract available.
2.
Juliet R, Loganathan A, Neeravi A, Bakthavatchalam Y, Veeraraghavan B, Manohar P, et al.
Front Microbiol
. 2024 Jun;
15:1391777.
PMID: 38887719
The emergence of multi-drug resistance in , causing food-borne infections, is a significant issue. With over 2,600 serovars in in sp., it is crucial to identify specific solutions for each...
3.
Loganathan A, Bozdogan B, Manohar P, Nachimuthu R
Front Pharmacol
. 2024 Apr;
15:1356179.
PMID: 38659581
The emergence of antibiotic resistance is a significant challenge in the treatment of bacterial infections, particularly in patients in the intensive care unit (ICU). Phage-antibiotic combination therapy is now being...
4.
Manohar P, Loh B, Nachimuthu R, Leptihn S
Sci Rep
. 2024 Apr;
14(1):9354.
PMID: 38653744
Phage-antibiotic combinations to treat bacterial infections are gaining increased attention due to the synergistic effects often observed when applying both components together. Most studies however focus on a single pathogen,...
5.
Manohar P, Loh B, Turner D, Tamizhselvi R, Mathankumar M, Elangovan N, et al.
Front Microbiol
. 2024 Apr;
15:1344962.
PMID: 38559352
Infections caused by are becoming increasingly difficult to treat due to the emergence of strains that have acquired multidrug resistance. Therefore, phage therapy has gained attention as an alternative to...
6.
Loganathan A, Nachimuthu R
Asian Biomed (Res Rev News)
. 2023 Aug;
16(4):191-199.
PMID: 37551171
Background: is a pathogen endemic in India and sometimes deadly for patients in intensive care units. Objectives: To determine the antibiotic-resistance pattern, biofilm forming ability, and clonal type of from...
7.
Manohar P, Loganathan A, Nachimuthu R, Loh B, Ma L, Turner D, et al.
Microbiol Resour Announc
. 2022 Oct;
11(11):e0074022.
PMID: 36222703
We describe the complete genome sequence of bacteriophage Motto, which infects clinical strains of Pseudomonas aeruginosa. Motto is a T1-like siphovirus related to members of the family and has a...
8.
Arumugam S, Manohar P, Sukumaran S, Sadagopan S, Loh B, Leptihn S, et al.
BMC Microbiol
. 2022 Jul;
22(1):187.
PMID: 35909125
Background: Pseudomonas aeruginosa is an opportunistic pathogen that can cause a variety of infections in humans, such as burn wound infections and infections of the lungs, the bloodstream and surgical...
9.
Lopes B, Hanafiah A, Nachimuthu R, Muthupandian S, Md Nesran Z, Patil S
Molecules
. 2022 May;
27(9).
PMID: 35566343
Just over a million people died globally in 2019 due to antibiotic resistance caused by ESKAPE pathogens (, , , , , and species). The World Health Organization (WHO) also...
10.
Manohar P, Loh B, Elangovan N, Loganathan A, Nachimuthu R, Leptihn S
Microbiol Spectr
. 2022 Feb;
10(1):e0139321.
PMID: 35171008
In order to establish phage therapy as a standard clinical treatment for bacterial infections, testing of every phage to ensure the suitability and safety of the biological compound is required....